Nano4 Global focuses on the development of the NANO4 platform. It is a nanotechnology platform applied to diagnostics that provides simple, easy and fast colorimetric detection of DNA and RNA with single base selectivity. It can therefore be used in a wide range of applications of which some in process of validations like: tuberculosis, antibiotic resistance or Zika, some types of cancers (e.g. leukemia and other indications being tested like lung or colon).
The Nano4 project has several fundamental goals, such as:
• Speed: being able to test at point of need, reducing time to result from several days at central lab to few minutes at day hospital or emergency room.
• Faster decision-making: especially in cases of epidemics, from two days to a week is the waiting time for lab results that can cost lives and where emotional trauma can be deep
• Triage: in rescue situations, such as the looming ZIKA epidemic, immediate information that helps to sort people on their need for treatment which can maximize the number of healthy survivors.
• A reduction in waiting time: high-dependency post-operative care time, emergency room time, number of outpatient clinic visits, and number of hospital beds required. Nano4 can have a major impact and ensure optimal use of professional time.
With our feasibility study, our objective was to make sure that NANO4 platform and clinical studies were viable and market oriented and, furthermore, we have also proceeded with the assessment of our market, business model and risks of project deployment. It was also important to plan our work schedule for the next two years of Phase 2 project, as well as our business plan. We have also aimed to define our IPR strategy.
